Filing Flows › Health Care › McKesson (MCK)

McKesson (MCK) earnings and revenue breakdown

Latest: Q2 FY27 · 10-Q filed Nov 4, 2026 · McKesson (MCK) Q2 FY27 earnings results →

Q2 FY27 Revenue up 8% year over year to $111.0B · 1¢ of every $1 of revenue kept as net profit · operating margin 1.4%

McKesson made $111.0B in Q2 FY27 (+8% Y/Y). Operating margin 1.4%, net earnings $1.2B. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

Embed this chart on your site

Picture with a link (blogs, newsletters, forums)<a href="https://filing-flows.com/c/mck/"><img src="https://raw.githubusercontent.com/eurikamonica/filing-flows/media/og/mck-revenue-breakdown-sankey.jpg?v=17a211f9db" alt="McKesson Q2 FY27 revenue breakdown: Sankey diagram of revenue, costs, profit and cash flow" width="600" style="max-width:100%;height:auto"></a><br><small>McKesson Q2 FY27 revenue breakdown — <a href="https://filing-flows.com/c/mck/">Filing Flows</a></small>Interactive chart<iframe src="https://filing-flows.com/c/mck/embed/" width="100%" height="460" style="border:0;max-width:900px" loading="lazy" title="McKesson Q2 FY27 revenue breakdown: Sankey diagram of revenue, costs, profit and cash flow"></iframe><br><small>McKesson Q2 FY27 revenue breakdown — <a href="https://filing-flows.com/c/mck/">Filing Flows</a></small>

Free to use with the credit line. Click a box to select the code.

What changed this quarter

Quarterly history

Charts

Interactive views

The same charts as the app — open one to draw it.

Customers and suppliers named in filings

Sells to

• CVS — 24% of its revenue · Stated in 10-K (sentence) · source
• NXPL · Stated in 10-K (named, share not stated) · source

Buys from

• CHRS — 43% of the supplier’s revenue · Stated in 10-K (XBRL) · source
• RIGL — 42% of the supplier’s revenue · Stated in 10-K (customer table) · source
• ADCT — 39% of the supplier’s revenue · Stated in 10-K (customer table) · source
• ALKS — 38% of the supplier’s revenue · Stated in 10-K (sentence) · source
• BMY — 36% of the supplier’s revenue · Stated in 10-K (XBRL) · source
• AMGN — 34% of the supplier’s revenue · Stated in 10-K (XBRL) · source
• PCRX — 31% of the supplier’s revenue · Stated in 10-K (sentence) · source
• PFE — 25% of the supplier’s revenue · Stated in 10-K (XBRL) · source
• AMPH — 24% of the supplier’s revenue · Stated in 10-K (XBRL) · source
• ONC — 18% of the supplier’s revenue · Stated in 10-K (XBRL) · source
• BHC — 16% of the supplier’s revenue · Stated in 10-K (customer table) · source
• AKBA — 12% of the supplier’s revenue · Stated in 10-K (customer table) · source

About McKesson

McKesson Corporation together with its subsidiaries (collectively, the “Company,” “McKesson,” “we,” “our,” or “us” and other similar pronouns), which traces its business roots to 1833, is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references in this document to a particular year refer to the Company’s fiscal year. The Company was incorporated on July 7, 1994 in the State of Delaware.

In its own words, from its 10-K, filed May 8, 2026.

McKesson against its Wholesale-Drugs, Proprietaries & Druggists' Sundries peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +8% against the peers' median +5%. Operating margin: 1.4% against the peers' median 1.3%.

Source: McKesson 10-Q on SEC EDGAR · CIK 927653 · Wholesale-Drugs, Proprietaries & Druggists' Sundries

中文版：McKesson（MCK）财报

Español · Français